Drugs / CD19 CAR and PD-1 knock out engineered T-cells
CD19 CAR and PD-1 knock out engineered T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03298828 | Nov 2017 → Oct 2020 | Burkitt lymphoma, acute lymphoblastic leukemia | Third Military Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR and PD-1 knock out engineered T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03298828 ↗ |
| Modality | Cell therapy | “CD19 Chimeric Antigen Receptor (CAR) and PD-1 knock out engineered T-cells” NCT03298828 ↗ |
| Route | Intravenous | “will be given as an intravenous injection” NCT03298828 ↗ |